Država: Armenija
Jezik: angleščina
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
iohexol
GE Healthcare Ireland Limited
V08AB02
iohexol
350mg iodine/ml
solution for injection
(10) plastic vial 50ml
Prescription
Registered
2017-12-08
OMNIPAQUE 140 MG I/ML, 180 MG I/ML, 240 MG I/ML, 300 MG I/ML, 350 MG I/ML SOLUTION FOR INJECTION SPC IRELAND Page 1 of 21 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Omnipaque 140 mg I/ml, 180 mg I/ml, 240 mg I/ml, 300 mg I/ml, 350 mg I/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Iohexol 302 mg/ml equivalent to 140 mg/ml Iodine Iohexol 388 mg/ml equivalent to 180 mg/ml Iodine Iohexol 518 mg/ml equivalent to 240 mg/ml Iodine Iohexol 647 mg/ml equivalent to 300 mg/ml Iodine Iohexol 755 mg/ml equivalent to 350 mg/ml Iodine Iohexol is a non-ionic, monomeric, tri-iodinated, water-soluble X-ray contrast medium. The osmolality and viscosity values of Omnipaque 140, 180, 240, 300, 350 mg I/ml are as follows: Concentration Osmolality * Osm/kg H 2 O 37°C Viscosity (mPa s) 20°C 37°C 140 mg I/ml 0.29 2.3 1.5 180 mg I/ml 0.36 3.2 2.0 240 mg I/ml 0.51 5.6 3.3 300 mg I/ml 0.64 11.6 6.1 350 mg I/ml 0.78 23.3 10.6 * Method: Vapour - pressure osmometry. This medicinal product contains 0.012 mg sodium per ml, i.e. essentially sodium free. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Omnipaque injection is supplied ready to use as clear, colourless to pale yellow, sterile aqueous solution. OMNIPAQUE 140 MG I/ML, 180 MG I/ML, 240 MG I/ML, 300 MG I/ML, 350 MG I/ML SOLUTION FOR INJECTION SPC IRELAND Page 2 of 21 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. X-ray contrast medium for use in adults and children for angiography, urography,,myelography, CT-enhancement and studies of the gastrointestinal tract . In adults only, phlebography, lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage varies dependi Preberite celoten dokument